Routinely vaccinating adolescents against meningococcus: targeting transmission & disease

Changes in the Population Structure of InvasiveNeisseria meningitidisin the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure

(2015) Xin Wang et al.   JOURNAL OF INFECTIOUS DISEASES

First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak

(2015) L. A. McNamara et al.   PEDIATRICS

Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013

(2015) Michael Bröker et al.   Human Vaccines & Immunotherapeutics

Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)

(2014) Lina Pérez-Breva et al.   BMC INFECTIOUS DISEASES

Increase in Endemic Neisseria meningitidis Capsular Group W Sequence Type 11 Complex Associated With Severe Invasive Disease in England and Wales

(2014) Shamez N. Ladhani et al.   CLINICAL INFECTIOUS DISEASES

Evolving meningococcal immunization strategies

(2014) Marco Aurélio Sáfadi et al.   Expert Review of Vaccines

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

(2014) Robert C Read et al.   LANCET

Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study

(2014) Rodrigo Lopez Castelblanco et al.   LANCET INFECTIOUS DISEASES

Epidemiology of invasive meningococcal disease in the Netherlands, 1960–2012: an analysis of national surveillance data

(2014) Merijn W Bijlsma et al.   LANCET INFECTIOUS DISEASES

Timing of an Adolescent Booster after Single Primary Meningococcal Serogroup C Conjugate Immunization at Young Age; An Intervention Study among Dutch Teenagers

(2014) Susanne P. Stoof et al.   PLoS One

Genetic Diversity and Levels of Expression of Factor H Binding Protein among Carriage Isolates of Neisseria meningitidis

(2014) Ludovic Lemée et al.   PLoS One

Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification

(2014) M. Garrido-Estepa et al.   VACCINE

Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study

(2014) H. Christensen et al.   BMJ-British Medical Journal

Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study

(2013) Charissa Borja-Tabora et al.   BMC INFECTIOUS DISEASES

Meningococcal Polysaccharide AO-Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years

(2013) Socorro Lupisan et al.   Clinical and Vaccine Immunology

Update on adolescent immunizations

(2013) Tali Capua et al.   CURRENT OPINION IN PEDIATRICS

The burden and impact of severe and long-term sequelae of meningococcal disease

(2013) Andrew Vyse et al.   Expert Review of Anti-Infective Therapy

Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study

(2013) DM Daugla et al.   LANCET

Meningococcal Serogroup A, C, W135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands

(2013) Hiltsje Hepkema et al.   PLoS One

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age

(2013) S. A. Halperin et al.   Journal of the Pediatric Infectious Diseases Society

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands

(2012) Patricia Kaaijk et al.   BMC INFECTIOUS DISEASES

Prevalence of Serum Bactericidal Antibody to Serogroup C Neisseria meningitidis in England a Decade after Vaccine Introduction

(2012) David A. Ishola et al.   Clinical and Vaccine Immunology

Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity

(2012) Paul A. Kristiansen, Fabien Diomandé, Absatou Ky Ba, Idrissa Sanou, Abdoul–Salam Ouédraogo, Rasmata Ouédraogo, Lassana Sangaré, Denis Kandolo, Flavien Aké, Inger Marie Saga, Thomas A. Clark, Lara Misegades, Stacey W. Martin, Jennifer Dolan Thomas, Sylvestre R. Tiendrebeogo, Musa Hassan-King, Mamoudou H. Djingarey, Nancy E. Messonnier, Marie-Pierre Préziosi, F. Marc LaForce, Dominique A. Caugant   CLINICAL INFECTIOUS DISEASES

Meningococcal disease in the Middle East and North Africa: an important public health consideration that requires further attention

(2012) Mehmet Ceyhan et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Epidemiology of invasive meningococcal disease in Germany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine

(2012) Wiebke Hellenbrand et al.   JOURNAL OF INFECTION

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

(2012) María Elena Santolaya et al.   LANCET

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

(2012) Peter C Richmond et al.   LANCET INFECTIOUS DISEASES

Effectiveness and Cost of Immunization Recall at School-Based Health Centers

(2012) A. Kempe et al.   PEDIATRICS

Middle School Vaccination Requirements and Adolescent Vaccination Coverage

(2012) E. Bugenske et al.   PEDIATRICS

The changing epidemiology of meningococcal disease in North America 1945–2010

(2012) Carmen Baccarini et al.   Human Vaccines & Immunotherapeutics

Carriage ofNeisseria meningitidisin Europe: a review of studies undertaken in the region

(2011) Montse Soriano-Gabarró et al.   Expert Review of Anti-Infective Therapy

Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults

(2011) Nancy Bermal et al.   Human vaccines & immunotherapeutics

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age

(2011) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial

(2011) Lars Østergaard et al.   VACCINE

Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity

(2010) H. Campbell et al.   Clinical and Vaccine Immunology

The epidemiology of meningococcal disease and the impact of vaccines

(2010) Ameneh Khatami et al.   Expert Review of Vaccines

Meningococcal carriage by age: a systematic review and meta-analysis

(2010) Hannah Christensen et al.   LANCET INFECTIOUS DISEASES

Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents

(2009) Lisa A. Jackson et al.   CLINICAL INFECTIOUS DISEASES

Evidence for Capsule Switching between Carried and Disease-Causing Neisseria meningitidis Strains

(2009) A. J. Beddek et al.   INFECTION AND IMMUNITY

Increasing Adolescent Vaccination: Barriers and Strategies in the Context of Policy, Legal, and Financial Issues

(2009) Carol A. Ford et al.   JOURNAL OF ADOLESCENT HEALTH

Risk Factors for Meningococcal Disease in Students in Grades 9–12

(2009) Lee H. Harrison et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents

(2009) Lisa A. Jackson et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Meningococcal carriage and disease—Population biology and evolution

(2009) Dominique A. Caugant et al.   VACCINE

The Promise and Challenge of Adolescent Immunization

(2008)   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the United States

(2008) Ismael R. Ortega Sanchez et al.   CLINICAL INFECTIOUS DISEASES

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

(2008) Martin C. J. Maiden et al.   JOURNAL OF INFECTIOUS DISEASES

Vaccination Coverage in 14-Year-Old Adolescents: Documentation, Timeliness, and Sociodemographic Determinants

(2008) C. Vandermeulen et al.   PEDIATRICS

Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae

(2008) Caroline L. Trotter et al.   VACCINE

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

(2008) Lars Østergaard et al.   VACCINE